Fig. 8: Comparison of SARS-CoV-2–specific humoral responses in PLWH receiving the monovalent or bivalent booster.
From: Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV
Fold-increase (T1/T0 ratio) of total RBD-binding (a) and RBD-blocking antibodies (b) against WT and BA.4/5 virus in PLWH (without previous SARS-CoV-2 infection) receiving monovalent (MV) original (n = 15) or bivalent (BV) original–BA.4/5 booster (n = 16). Values equals to 1 indicate no increase, while values higher than 1 indicate an increase. Green/orange squares and diamonds: individual values; black bars: median values; green/orange boxes: interquartile ranges; statistical analyses: Mann–Whitney test (comparison between PLWH receiving MV or BV booster; P values < 0.05 showed in green or orange above solid lines) and Wilcoxon test (comparison between WT- and BA.4/5-reactive antibodies; P values < 0.05 showed in black above dashed lines).
